Are The 90s Back? Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High
This article was originally published in Pharmaceutical Approvals Monthly
With 45 new molecular entities and novel biologics cleared in 2012, FDA approvals have reached a level not seen since the mid-1990s, the golden age of modern medicine. The group reflects a boom in oncology; other drug development trends like orphan diseases and personalized medicine held steady. Big pharma contributed just over a third of the 2012 class, with Pfizer regaining the lead with five novel approvals.